Discover and read the best of Twitter Threads about #braf

Most recents (4)

1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress.
@myESMO #LCSM #FOAMed Image
2) The faculty for this outstanding program were @peters_solange (Chair) πŸ‡¨πŸ‡­, @HosseinBorghaei πŸ‡ΊπŸ‡Έ, Natasha Leighl MD πŸ‡¨πŸ‡¦, and @dplanchard πŸ‡«πŸ‡·. A truly international roster of experts in #oncology!
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
3) This program is supported by an educational grant from Sanofi. Statement of accreditation and author disclosures are at oncologytweetorials-ce.com/disclosures/.
Read 24 tweets
#OncoAlert Report @JTOonline on PDL1 variability in metastatic #NSCLC. A lot of intriguing information on this increasingly imperfect biomarker. Important to understand what's driving the heterogeneity and how it impacts treatment. @IASLC #LCSM

jto.org/article/S1556-…
#OncoAlert In an analysis of 1398 patients with NSCLC they looked at patterns of PD-L1 expression and the impact of disease site and prior therapy. In a subset who received checkpoint inhibitors, they also looked at outcomes. Could influence how we look at PDL1 IHC. #LCSM
Lesson 1: PD-L1 varies by site. Previously reported. If the biopsy is from liver or adrenal, PDL1 runs higher. Brain and bone, PDL1 tends to be low. Some sets have small numbers but interesting trends and may reflect differences in the immune microenvironment #OncoAlert #LCSM Image
Read 7 tweets
#DCLUNG19 Daunting task of all non-EGFR/ALK drivers in #NSCLC handled easily by @alexdrilon - in #ROS1, note that not all ALK inhibitors are ROS1 inhibitors. Variation in CNS activity. Many active drugs to consider. #LCSM #LCAM ImageImageImage
#DCLUNG19 Highly active, CNS penetrant and well tolerated TKIs for #RET and #NTRK fusion positive cancers, outlined by expert @alexdrilon ImageImageImageImage
#DCLUNG19 Dabrafenib and trametinib active in #BRAF but be sure it’s V600E! Three drugs with breakthrough designation for #METex14. HER2 is a target but not copy number for #NSCLC, its mutations (usually ex20). #LCSM #LCAM ImageImageImageImage
Read 5 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!